View Older Stories View More Recent Stories

Nov 2, 2021 08:30AM Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
Oct 25, 2021 09:00AM Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies
Sep 22, 2021 08:33AM Cellectar Biosciences (CLRB) Announces Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in R/R Head and Neck Cancer
Sep 22, 2021 08:30AM Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer
Sep 15, 2021 04:01PM Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Aug 18, 2021 08:31AM Cellectar Biosciences (CLRB) Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia
Aug 18, 2021 08:30AM Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia
Aug 16, 2021 08:30AM Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131
Aug 9, 2021 08:30AM Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
Jul 13, 2021 09:00AM Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
Jul 12, 2021 08:33AM Cellectar Biosciences (CLRB) Announces Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates
Jul 12, 2021 08:30AM Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)
Jul 8, 2021 08:30AM Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
Jun 24, 2021 08:35AM Cellectar Biosciences (CLRB) Announces Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
Jun 24, 2021 08:30AM Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
Jun 4, 2021 09:00AM Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 20, 2021 08:30AM Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 14, 2021 09:00AM Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
May 10, 2021 08:30AM Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
Apr 27, 2021 08:39AM Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
Mar 11, 2021 08:30AM Cellectar to Participate at Upcoming Institutional Investor Conferences
Mar 9, 2021 09:00AM Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates
Mar 5, 2021 08:30AM Cellectar to Participate at Upcoming Institutional Investor Conferences
Mar 2, 2021 08:30AM Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update
Feb 10, 2021 08:30AM Cellectar to Present at BIO CEO & Investor Digital Conference
Jan 27, 2021 08:34AM Cellectar (CLRB) Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia
Jan 27, 2021 08:30AM Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia
Jan 12, 2021 08:30AM Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia
Dec 28, 2020 04:05PM Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
Dec 23, 2020 08:41AM Cellectar Biosciences (CLRB) Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
Dec 23, 2020 08:38AM Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
Dec 22, 2020 05:28PM Cellectar Biosciences (CLRB) Announces Proposed Underwritten Public Offering and Concurrent Private Placement
Dec 22, 2020 05:27PM Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement
Nov 9, 2020 08:44AM Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Nov 5, 2020 09:05AM Cellectar Biosciences' (CLRB) CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors
Nov 5, 2020 09:00AM Cellectar Biosciences’ CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors
Sep 10, 2020 08:00AM Cellectar Biosciences to Present at Two Upcoming Investor Conferences
Sep 9, 2020 08:03AM Cellectar Biosciences (CLRB) Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients
Sep 9, 2020 08:00AM Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients
Aug 17, 2020 10:01AM Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA
Aug 10, 2020 08:00AM Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
Aug 4, 2020 08:00AM Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting
Jul 21, 2020 08:00AM Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting
Jul 1, 2020 08:00AM Cellectar Appoints Dr. John Friend as Chief Medical Officer
Jun 11, 2020 08:30AM Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles
Jun 5, 2020 04:01PM Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering
Jun 3, 2020 09:01AM Cellectar Biosciences (CLRB) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock, Warrants
Jun 3, 2020 09:00AM Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering
Jun 1, 2020 08:00AM Cellectar Granted SME Status by the European Medicines Agency
May 26, 2020 07:46AM Cellectar Biosciences (CLRB) Receives FDA Fast Track Designation for CLR 131 in LPL/WM
View More Recent Stories View Older Stories